These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7545025)

  • 1. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
    Leith CP; Chen IM; Kopecky KJ; Appelbaum FR; Head DR; Godwin JE; Weick JK; Willman CL
    Blood; 1995 Sep; 86(6):2329-42. PubMed ID: 7545025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
    Leith CP; Kopecky KJ; Chen IM; Eijdems L; Slovak ML; McConnell TS; Head DR; Weick J; Grever MR; Appelbaum FR; Willman CL
    Blood; 1999 Aug; 94(3):1086-99. PubMed ID: 10419902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia.
    Pearson L; Leith CP; Duncan MH; Chen IM; McConnell T; Trinkaus K; Foucar K; Willman CL
    Leukemia; 1996 Aug; 10(8):1274-82. PubMed ID: 8709631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study.
    Leith CP; Kopecky KJ; Godwin J; McConnell T; Slovak ML; Chen IM; Head DR; Appelbaum FR; Willman CL
    Blood; 1997 May; 89(9):3323-9. PubMed ID: 9129038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group.
    Paietta E; Andersen J; Racevskis J; Ashigbi M; Cassileth P; Wiernik PH
    Blood Rev; 1995 Mar; 9(1):47-52. PubMed ID: 7540903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
    Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
    Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
    Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
    Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
    van den Heuvel-Eibrink MM; van der Holt B; Burnett AK; Knauf WU; Fey MF; Verhoef GE; Vellenga E; Ossenkoppele GJ; Löwenberg B; Sonneveld P
    Ann Hematol; 2007 May; 86(5):329-37. PubMed ID: 17340137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia.
    Sincock PM; Ashman LK
    Leukemia; 1997 Nov; 11(11):1850-7. PubMed ID: 9369417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis.
    Drach J; Zhao S; Drach D; Körbling M; Engel H; Andreeff M
    Leuk Lymphoma; 1995 Feb; 16(5-6):419-24. PubMed ID: 7540457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric analysis of apoptotic and multi-drug resistance phenotypes according to the blast cell maturation stage in elderly patients with acute myeloid leukemia.
    Suárez L; Vidriales B; García-Laraña J; López A; Martínez R; Martín-Reina V; Tormo M; González-San Miguel JD; Lavilla E; García-Boyero R; Orfao A; San Miguel JF;
    Haematologica; 2001 Dec; 86(12):1287-95. PubMed ID: 11726321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.
    Marcelletti JF; Sikic BI; Cripe LD; Paietta E
    Cytometry B Clin Cytom; 2019 Jan; 96(1):57-66. PubMed ID: 30334334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented expression of P-gp/multi-drug resistance gene by all-trans retinoic acid in monocytic leukemic cells.
    Tokura Y; Shikami M; Miwa H; Watarai M; Sugamura K; Wakabayashi M; Satoh A; Imamura A; Mihara H; Katoh Y; Kita K; Nitta M
    Leuk Res; 2002 Jan; 26(1):29-36. PubMed ID: 11734301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia.
    van der Kolk DM; de Vries EG; Noordhoek L; van den Berg E; van der Pol MA; Müller M; Vellenga E
    Leukemia; 2001 Oct; 15(10):1544-53. PubMed ID: 11587212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
    Guerci A; Merlin JL; Missoum N; Feldmann L; Marchal S; Witz F; Rose C; Guerci O
    Blood; 1995 Apr; 85(8):2147-53. PubMed ID: 7536492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
    Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
    Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients.
    Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
    Blood; 1998 Jun; 91(12):4480-8. PubMed ID: 9616142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
    Ho MM; Hogge DE; Ling V
    Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
    Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
    Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.